Intech Investment Management LLC reduced its position in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 16.5% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 254,691 shares of the biopharmaceutical company’s stock after selling 50,379 shares during the period. Intech Investment Management LLC’s holdings in Bristol Myers Squibb were worth $15,893,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of BMY. BlackRock Inc. raised its stake in shares of Bristol Myers Squibb by 5.1% during the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock worth $10,393,783,000 after acquiring an additional 8,702,106 shares in the last quarter. State Street Corp lifted its position in Bristol Myers Squibb by 7.3% during the second quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock valued at $6,093,755,000 after acquiring an additional 7,192,724 shares during the last quarter. Primecap Management Co. CA acquired a new stake in Bristol Myers Squibb in the second quarter valued at approximately $1,436,115,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Bristol Myers Squibb by 0.5% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 22,839,010 shares of the biopharmaceutical company’s stock valued at $1,315,984,000 after acquiring an additional 119,690 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in Bristol Myers Squibb by 2.9% in the first quarter. Dimensional Fund Advisors LP now owns 18,762,589 shares of the biopharmaceutical company’s stock worth $1,137,847,000 after purchasing an additional 520,330 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.
Bristol Myers Squibb Stock Down 0.7%
BMY stock opened at $62.96 on Tuesday. The firm has a 50 day moving average of $61.82 and a 200 day moving average of $60.35. The stock has a market capitalization of $128.69 billion, a PE ratio of 13.96, a price-to-earnings-growth ratio of 0.32 and a beta of 0.20. The company has a quick ratio of 1.44, a current ratio of 1.59 and a debt-to-equity ratio of 1.79. Bristol Myers Squibb Company has a 52 week low of $45.26 and a 52 week high of $68.64.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.25. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The business had revenue of $13.07 billion for the quarter, compared to analyst estimates of $12.72 billion. During the same quarter in the prior year, the business posted $1.63 EPS. Bristol Myers Squibb’s revenue for the quarter was up 6.9% compared to the same quarter last year. Sell-side analysts forecast that Bristol Myers Squibb Company will post 6.46 earnings per share for the current year.
Bristol Myers Squibb Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Friday, October 2nd were given a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 4.0%. The ex-dividend date of this dividend was Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 55.88%.
Insider Buying and Selling at Bristol Myers Squibb
In other Bristol Myers Squibb news, Director Julia A. Haller sold 3,800 shares of the business’s stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $63.31, for a total transaction of $240,578.00. Following the sale, the director owned 30,279 shares in the company, valued at approximately $1,916,963.49. The trade was a 11.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the sale, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. The trade was a 2.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.05% of the stock is owned by corporate insiders.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on BMY. Morgan Stanley reduced their price target on Bristol Myers Squibb from $41.00 to $40.00 and set an “underweight” rating on the stock in a research report on Friday, October 30th. William Blair reissued a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, October 12th. Piper Sandler lowered their price objective on Bristol Myers Squibb from $82.00 to $78.00 and set an “overweight” rating for the company in a research report on Monday, October 26th. Wells Fargo & Company dropped their target price on Bristol Myers Squibb from $65.00 to $60.00 and set an “equal weight” rating on the stock in a research note on Tuesday, October 13th. Finally, Zacks Research lowered Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 22nd. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb has an average rating of “Hold” and an average target price of $65.46.
Read Our Latest Stock Report on Bristol Myers Squibb
Bristol Myers Squibb Company Profile
Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.
Recommended Stories
- Five stocks we like better than Bristol Myers Squibb
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
